文章来源：神经未来 转载要求：可以直接转载，请在文首注明来源 2026年2月5日，证监会IPO辅导公示系统显示， 博睿康 已向上海证监局提交IPO辅导备案，正式启动上市进程 。 作为国内脑机接口（BCI）领域最早一批系统级企业之一，博睿康的核心产品为 微创植入式脑机接口系统 NEO 。据公开信息， NEO 已于 2025 年完成注册性临床试验，并进入国家药监局创新医疗器械特别审查程序， 有望成为 国内首个实现商业化落地 的植入式脑机接口产品 。 在海外脑机接口持续取得阶段性突破、国内政策与临床同步加速的背景下，博睿康的 IPO 动向，被视为中国医疗级 BCI 从"科 研主导"迈向"产业化验证"的重要信号。 # 海内外脑机接口进展提速，产业关注度持续升温 近一个月内，脑机接口赛道连续释放多重信号： 海外公司在侵入式技术路径上的持续突破，与国内企业在监管、临床和政策端的同步推进，使脑机接口从"前沿探索"逐步进入 可被资本 和产业评估的阶段 。 # 医疗仍是 BCI 最大基本盘，市场规模正在被重新评估 从全球视角看， 医疗健康是脑机接口当前最成熟、占比最高的应用方向 。 综合多家研究机构测算，医疗领域通常占整体 B ...

Core Viewpoint - The integration of AI and brain-computer interfaces (BCIs) is accelerating the commercialization growth cycle, driven by technological iterations and policy support under the 14th Five-Year Plan [1][3]. Group 1: Technology Development - BCIs enable bidirectional information transmission, creating a collaborative pathway between humans and machines, with core functions including neural signal interpretation and external device control [2]. - Various technological routes are developing in parallel: non-invasive methods are currently mainstream due to their ease of use and safety, while semi-invasive and invasive methods offer advantages in risk-efficiency and high spatial resolution, respectively [2]. - The deep integration of AI with BCIs is a significant trend, enhancing signal decoding precision and efficiency through machine learning algorithms, leading to the evolution towards a "brain-machine intelligent community" [2]. Group 2: Market Dynamics - The global competition in the BCI industry is intensifying, with the US focusing on invasive technologies and China making breakthroughs in non-invasive and language decoding fields, while also catching up in invasive technologies [3]. - Domestic policies are supporting the BCI industry through the 14th Five-Year Plan, establishing a comprehensive support system that includes technological innovation, application scenarios, and medical insurance payment [3]. - Capital investment in the BCI sector is expected to see significant growth by 2025, with a notable increase in financing events and amounts, indicating a trend towards early-stage investment and a concentration of capital in leading enterprises [3]. Group 3: Application Scenarios - The healthcare sector is currently the most established application area for BCIs, with successful implementations in hearing impairment, tremor treatment, and motor rehabilitation, supported by a robust medical insurance payment system [4]. - Other application scenarios are rapidly expanding, including consumer markets targeting both disabled and healthy populations, and industrial applications focusing on high-risk, high-precision tasks transitioning from experimental validation to commercialization [4]. - Leading companies are building competitive advantages through comprehensive R&D, industry-academia collaboration, and multi-scenario layouts, creating differentiated strengths in non-invasive technology applications and AI integration [4].

Market Overview - The A-share market experienced a decline, with the Shanghai Composite Index closing at 4075.92, down 0.64%, and the Shenzhen Component Index down 1.44% at 13952.71 [8][9] - The overall market sentiment showed a decrease in trading volume, with total market turnover at 21,942.8 billion, a reduction of 3,089.83 billion from the previous trading day [9][11] Industry Dynamics - The brain-computer interface company, Borui Kang, has initiated its listing guidance, indicating growth in the tech sector [26] - The photovoltaic industry is expected to maintain stable installation levels during the 14th Five-Year Plan, with annual new installations projected between 238-287 GW in China [28] - The global liquid crystal television panel shipment is forecasted to increase by 3.4% in 2025, with mainland manufacturers surpassing a 70% market share for the first time [30] - The global display market is expected to grow by 1.1% in 2025, driven by a significant increase in OLED display shipments [33] Company Updates - Qilu Bank reported a 5.12% year-on-year increase in operating revenue for 2025, reaching 13.135 billion, with net profit rising by 14.58% to 5.713 billion [39][41] - The company maintained a non-performing loan ratio of 1.05%, a decrease of 0.14 percentage points from the previous year, indicating improved asset quality [41] Economic Insights - In January 2026, 4.92 million new A-share accounts were opened, a 213% increase year-on-year, reflecting growing investor interest [35] - The logistics industry in China reported a January 2026 business activity index of 51.2, indicating continued expansion despite a slight month-on-month decline [17]

Company Overview - Brain-computer interface company, BoRuiKang Technology (Shanghai) Co., Ltd., has completed its IPO counseling registration on February 4, 2026, with CITIC Securities as the counseling broker, marking the official start of its Sci-Tech Innovation Board IPO process [1][2][3] - Established in November 2011, BoRuiKang's core team includes experts from Tsinghua University's Neural Engineering Laboratory and clinical neuroscience, focusing on the research, production, and technical services of brain-computer interface systems [3][4] - The company has developed products for clinical diagnosis and research education, including digital EEG machines and transcranial electrical stimulation systems, with some products already receiving medical device registration [3][4] Product Development - BoRuiKang's flagship product, the NEO wireless minimally invasive brain-computer interface system, is the world's first to use an epidural implant with fully wireless transmission design [3][4] - NEO employs a "semi-invasive" technique, implanting coin-sized electrodes beneath the skull but outside the dura mater, allowing proximity to neurons without direct contact, thus avoiding damage to neural tissue [4] - The NEO system has undergone successful clinical trials, with 32 patients having completed implantation across 11 hospitals, achieving a 100% success rate in primary clinical endpoints [4][5] Regulatory Progress - NEO is set to submit a Class III innovative medical device registration application to the National Medical Products Administration, potentially becoming the first marketed implantable brain-computer interface product in China [5] - The product's first version, NEO 1.0, is expected to be followed by a 2.0 version that will include additional features such as language decoding and small limb decoding [5] Financial Backing and Valuation - BoRuiKang has completed multiple rounds of financing, with notable investors including Sequoia China and Baidu Ventures, achieving a post-investment valuation of 3.5 to 4 billion yuan by the end of 2025 [5][6] - The company has raised a total of 1.2 million yuan in angel funding and 30 million yuan in Pre-A funding, among other financing rounds [5] Industry Context - The brain-computer interface industry is experiencing significant growth opportunities in China, supported by favorable policies and market conditions [9][10] - The Ministry of Industry and Information Technology and other departments have included brain-computer interfaces in key future industry cultivation, with projections indicating the market could exceed 120 billion yuan by 2040 [10]

Group 1 - The core theme for Wuxi in 2026 is to implement the important speech of General Secretary Xi Jinping on Jiangsu's work, focusing on building a modern industrial city and contributing to the new chapter of "strong, prosperous, beautiful, and high" Jiangsu modernization [1] - Wuxi aims to elevate its industrial system by emphasizing the real economy, maintaining the manufacturing industry's value-added proportion, and promoting high-quality development of the productive service industry. The city will focus on artificial intelligence and commercial aerospace, enhancing strategic emerging industries and high-tech industries [1] - The city will actively integrate into the Shanghai (Yangtze River Delta) International Science and Technology Innovation Center, deepen cooperation in the Su-Xi-Chang metropolitan area, and utilize platforms like the West Port Special Zone to gather global resources and promote deep integration of technological and industrial innovation [1] Group 2 - Wuxi is committed to improving the water quality of Taihu Lake by addressing issues raised in the central inspection feedback, implementing high-standard governance, and ensuring that the water quality in Wuxi's Taihu area stabilizes at Class III [2] - The governance of Taihu Lake will be leveraged to promote carbon reduction, pollution control, and green expansion, aiming to create a high-quality livable city that balances population, talent, and economic growth [2] - The city will focus on common prosperity by improving public resource allocation mechanisms, developing micro-profit public utilities led by state-owned enterprises, and addressing public concerns regarding education, healthcare, and employment [2]

Group 1 - The core viewpoint of the article emphasizes the importance of direct communication between enterprises and government departments, showcasing a proactive approach to addressing business needs and fostering growth in the Jinjiang District [1][2] - The Jinjiang District government is committed to enhancing the "Bailu Plan" and will utilize the High-Growth Enterprise Development Promotion Center to provide comprehensive services aimed at resolving development bottlenecks [2] - The meeting highlighted the release of research findings on the "Industrial Renewal Index and High-Growth Enterprise Development," along with the first batch of innovative products for 2026, indicating a strategic focus on future industry layout [2] Group 2 - During the meeting, enterprises such as Chengdu Chip Brain Technology and Xingyuan Space presented their demands, which were promptly addressed by relevant government departments, demonstrating a responsive governance model [1] - The Jinjiang District Talent Office committed to expediting the recognition process for master's degree holders through a mobile application, aiming for completion within 10 to 15 working days [1] - The district's technology bureau plans to collaborate with Chip Brain Technology to apply for a provincial-level manufacturing innovation center for brain-machine interfaces, indicating a focus on advanced technology sectors [1]

Group 1 - The core idea of the news is that Elon Musk's business empire is accelerating vertical integration, with SpaceX acquiring xAI, which previously merged with social platform X, creating a super entity focused on space data centers and AI computing energy breakthroughs [2] - The "Big X Group" is a loose alliance centered around SpaceX, integrating xAI and X, with a valuation exceeding $1.25 trillion, and includes Tesla, The Boring Company, and Neuralink [2] - Musk's acquisition history shows a preference for centralized control, as seen with Tesla's $2 billion investment in xAI, indicating a potential for Neuralink to be integrated into the "Big X Group" to enhance overall valuation and support SpaceX's IPO plans [6] Group 2 - Neuralink, founded in 2016, focuses on invasive brain-machine interfaces, with plans for human implantation in 2024 and expansion into text translation and thought control by 2025 [5] - The synergy potential between Neuralink and xAI is significant, as xAI's Grok relies on real-time data, while Neuralink provides a direct interface for human thought, enabling a closed-loop brain-machine ecosystem [5][6] - Regulatory barriers are high for Neuralink due to its medical device nature, which may lead to data privacy and ethical concerns if integrated into a commercial entity like SpaceX or xAI [6] Group 3 - The probability of integration between Neuralink and the "Big X Group" is high, potentially occurring by late 2026 or early 2027, as Neuralink is seen as a key component in Musk's vision of understanding the universe [7] - If integration occurs, it would signify a leap towards a "super entity" that merges AI, space, and human intelligence, while if it does not happen, Neuralink may remain independent or align more closely with Tesla [7]

中新社天津2月5日电 (记者孙玲玲)全国首届脑机接口开发者大会近日在天津举行，会上揭晓"华瑙— 2025年度中国脑机接口十大进展"，其详细内容于5日晚正式对外发布。这些成果标志着中国脑机接口技 术正加速从实验室走向产业一线。 本次发布的十大进展聚焦产业核心环节：在标准层面，脑机接口医疗器械基础术语行业标准发布，填补 了标准体系空白；在技术前沿，可泛化与可解释的癫痫发作预测脑电大模型取得关键突破，首创融合大 语言模型的脑电—语义转换新范式；在临床转化上，"北脑一号"智能脑机系统植入式设备开展多中心临 床试验，已完成多例人体植入手术。 天津市环湖医院副院长岳伟参加上述大会时介绍，医院与脑机海河实验室以临床需求为导向，推动科研 创新成果精准对接临床需求，已形成包括上下肢运动康复、精神诊疗、神经重症等多项脑机接口临床综 合解决方案。 《加快北京市脑机接口创新发展行动方案(2025—2030年)》近日印发，系统规划了打造高水平脑机接口 创新与产业高地的蓝图；全国首个脑机接口未来产业集聚区"脑智天地"在上海启动；今年天津市政府工 作报告提出，其将争建国家脑机接口技术创新中心；江苏等地也通过设立省级研究院等方式推动产学研 ...

Core Viewpoint - The market is experiencing a phase of adjustment after a period of overheating, primarily due to expectations of tightening overseas liquidity and pressure from cyclical sector corrections [1][5]. Group 1: Market Outlook - February is identified as a rare performance vacuum period, with a stable situation in the Asia-Pacific region; however, the extended Spring Festival may lead to early profit-taking by some funds [6]. - The market is expected to exhibit a volatile pattern, emphasizing the importance of stock selection [6]. Group 2: Investment Opportunities in Medical Technology - The company remains optimistic about the ongoing wave of technological innovation in the medical and consumer sectors, particularly driven by AI and domestic industry advancements, which present investment opportunities in the Chinese capital market [7][8]. - Key areas of focus include AI in healthcare, brain-computer interfaces, surgical robots, AI-driven innovative drugs, innovative medical devices, and cell gene nucleic acid therapies [7][8]. Group 3: New Logic for Innovative Drugs - The previous BD (business development) trading model for innovative drugs is losing effectiveness, necessitating a new guiding logic for the capital market to foster a new market trend [9]. - Three potential directions for innovative drugs are identified: 1. Core value return, where the globalization of domestic innovative drugs does not require excessive speculation 2. Performance explosion, with some outbound platform-type innovative drug companies expected to show nonlinear profit releases 3. Positive cycle of BD trading, where market sentiment is cyclical, transitioning from excessive enthusiasm to extreme lows, leading to a significant drop in overseas BD expectations for many companies [9].

Group 1 - The core viewpoint is that the domestic brain-computer interface (BCI) industry in China has surpassed 650 companies, with a significant shift towards the medical and health sector due to increasing demand from patients with neurological diseases [1][2] - The number of newly registered BCI companies in China increased by approximately 50% year-on-year in 2025, indicating a growing interest and investment in this field [1] - Major players like OpenAI's Sam Altman and Elon Musk's Neuralink are driving the global interest in BCIs, with Neuralink announcing plans for device mass production within the year [1] Group 2 - The transition from consumer applications to medical health is driven by the rising number of patients suffering from conditions like stroke and Parkinson's disease, which traditional medical methods struggle to address [2] - There are significant challenges in making BCI technology widely accessible, including the high cost of invasive devices exceeding 500,000 yuan and the economic burden of non-invasive products on some families [2] - A call for a multi-faceted payment system involving medical insurance, commercial insurance, and personal payments has been made to alleviate financial pressures on patients [2]